Harnessing Noxa demethylation to overcome Bortezomib resistance in mantle cell lymphoma

Bortezomib (BZM) is the first proteasome inhibitor approved for relapsed Mantle Cell Lymphoma (MCL) with durable responses seen in 30%–50% of patients. Given that a large proportion of patients will not respond, BZM resistance is a significant barrier to use this agent in MCL. We hypothesized that a...

Volledige beschrijving

Bewaard in:
Bibliografische gegevens
Gepubliceerd in:Oncotarget
Hoofdauteurs: Leshchenko, Violetta V., Kuo, Pei-Yu, Jiang, Zewei, Weniger, Marc A., Overbey, Jessica, Dunleavy, Kieron, Wilson, Wyndham H., Wiestner, Adrian, Parekh, Samir
Formaat: Artigo
Taal:Inglês
Gepubliceerd in: Impact Journals LLC 2015
Onderwerpen:
Research Paper
Online toegang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4694993/
https://ncbi.nlm.nih.gov/pubmed/25714012
Tags: Voeg label toe
Geen labels, Wees de eerste die dit record labelt!

Gelijkaardige items